Please use this identifier to cite or link to this item:
Title: Screening and treatment of obstructive sleep apnea in acute coronary syndrome. A randomized clinical trial
Authors: Koo, Chieh-Yang 
Chua, Ai-Ping 
Kristanto, William
Koh, Esther Hui-Ting
Tan, Eugene Siang-Joo
Abd Rahman, Shaffinaz
Abd Gani, Munirah Binte
Chong, Jenny Pek-Ching
Aung, Aye-Thandar
Han, Tun-Oo
Chan, Siew-Pang 
Lowa, Adrian F
Yeo, Tiong-Cheng 
Chan, Mark Y 
Kojodjojo, Pipin 
Richards, Arthur Mark 
Lee, Chi-Hang 
Keywords: Clinical trial
Sleep apnea
Acute coronary syndrome
Risk factor
Issue Date: 15-Jan-2020
Citation: Koo, Chieh-Yang, Chua, Ai-Ping, Kristanto, William, Koh, Esther Hui-Ting, Tan, Eugene Siang-Joo, Abd Rahman, Shaffinaz, Abd Gani, Munirah Binte, Chong, Jenny Pek-Ching, Aung, Aye-Thandar, Han, Tun-Oo, Chan, Siew-Pang, Lowa, Adrian F, Yeo, Tiong-Cheng, Chan, Mark Y, Kojodjojo, Pipin, Richards, Arthur Mark, Lee, Chi-Hang (2020-01-15). Screening and treatment of obstructive sleep apnea in acute coronary syndrome. A randomized clinical trial. INTERNATIONAL JOURNAL OF CARDIOLOGY 299 : 20-25. ScholarBank@NUS Repository.
Abstract: Background: We evaluated the effects of sleep-study guided multidisciplinary therapy (SGMT) of obstructive sleep apnoea (OSA) in patients presenting with acute coronary syndrome. Methods: Eligible patients were randomized into (1) SGMT, comprised a sleep study during the index admission and continuous positive airway pressure and behavioral therapy for those with at least mild OSA or (2) standard therapy. The primary end point was the change in the plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level from baseline to the 7-month follow-up. Results: A total of 159 patients completed the trial. Of the 70 patients randomized to SGMT, 21 (30%), 15 (22%) and 27 (39%) were diagnosed with mild, moderate and severe OSA, respectively. Continuous positive airway pressure and a positional pillow were prescribed to 57 (91%) and 6 (9%) patients with OSA. Although plasma NT-proBNP levels were lower after 7 months compared to the baseline, the levels did not differ significantly between the SGMT and standard therapy groups at baseline (579 ± 1117 vs. 611 ± 899 pg/dL, p =. 851) or at 7 months (90 ± 167 vs. 93 ± 174 pg/dL, p =. 996). The changes in NT-proBNP levels from baseline to 7 months were similar with SGMT and standard therapy (−489 vs. –518 pg/dL, p =. 726). Similar findings were observed for the plasma ST2 and hs-CRP levels. Conclusions: OSA screening and multifaceted treatment during the sub-acute phase of acute coronary syndrome did not further reduce the levels of cardiovascular biomarkers when compared with standard therapy. Clinical Trial Registration: NCT02599298
ISSN: 01675273
DOI: 10.1016/j.ijcard.2019.07.003
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Screening and treatment of obstructive sleep apnea in acute coronary syndrome. A randomized clinical trial.pdfPublished version351.11 kBAdobe PDF




checked on May 14, 2022

Page view(s)

checked on May 12, 2022


checked on May 12, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.